Strategic partnerships Sucampo has a history of global collaborations for AMITIZA through partners like Takeda, Dr. Reddy’s Laboratories, Par Pharmaceuticals, and Parpharm. Opportunities may exist to re-engage or identify new co-promotion or licensing arrangements in regions where partnerships have lapsed or evolved.

Market focus With AMITIZA as a lead product and RESCULA in the portfolio, there is potential to target specialty gastroenterology and ophthalmology channels, especially in markets where Shown prior marketing efforts have shifted post 2024 partnership terminations.

Geographic footprint Headquartered in the US with operations in Japan, Switzerland, and the U.K. presents opportunities for regional market expansion, distribution deals, and regulatory-compliant commercialization partnerships in high-potential territories.

Financial scale Current revenue range and substantial funding indicate capacity for business development activities, co-development ventures, or milestone-driven partnerships to accelerate pipeline commercialization or expansion into adjacent therapeutic areas.

Leadership & governance Past leadership appointments and governance events suggest a responsive executive environment for strategic alliances; identify senior contacts (General Counsel, Corporate Secretary, regional leaders) to initiate engagement and build trust for BD opportunities.